CTLA4 and metastatic melanoma: However, their clinical utility remains controversial, and to the best of our knowledge, only one study applied the imPERCIST5 criteria to a series of patients treated with ipilimumab, and none in patients on first-line antiPD1 (or anti PD1/anti CTLA4 combination) for advanced/metastatic melanoma [16].